EUVIMEDEUVIMED entdecken
Crossref

Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance–Like Phenotype in Patients With Monoclonal Gammopathies

Leire Burgos, Luis-Esteban Tamariz-Amador iD, Noemi Puig iD, Maria-Teresa Cedena iD, Camila Guerrero iD, Tomas Jelínek iD, Sarah Johnson, Paolo Milani iD, Lourdes Cordon iD, Jose J Perez, Marta Lasa iD, Rosalinda Termini iD und 31 weitere

Journal of Clinical Oncology · 2023

DOI: 10.1200/jco.22.01916 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, 2023. Verfasst von Leire Burgos und 42 weiteren Autor:innen. Beteiligte Einrichtung: Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Universidad de Navarra, CCUN, IDISNA, CIBERONC, Pamplona, Spain. Hauptthemen laut MEDLINE: Monoclonal Gammopathy of Undetermined Significance, Immunoglobulin Light-chain Amyloidosis, Paraproteinemias, Multiple Myeloma. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 56 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The existence of patients with multiple myeloma (MM) and light-chain (AL) amyloidosis who present with a monoclonal gammopathy of undetermined significance (MGUS)–like phenotype has been hypothesized, but methods to identify this subgroup are not standardized and its clinical significance is not properly validated. PATIENTS AND METHODS An algorithm to identify patients having MGUS-like phenotype was developed on the basis of the percentages of total bone marrow (BM) plasma cells (PC) and of clonal PC within the BM PC compartment, determined at diagnosis using flow cytometry in 548 patients with MGUS and 2,011 patients with active MM. The clinical significance of the algorithm was tested and validated in 488 patients with smoldering MM, 3,870 patients with active MM and 211 patients with AL amyloidosis. RESULTS Patients with smoldering MM with MGUS-like phenotype showed significantly lower rates of disease progression (4.5% and 0% at 2 years in two independent series). There were no statistically significant differences in time to progression between treatment versus observation in these patients. In active newly diagnosed MM, MGUS-like phenotype retained independent prognostic value in multivariate analyses of progression-free survival (PFS; hazard ratio [HR], 0.49; P = .001) and overall survival (OS; HR, 0.56; P = .039), together with International Staging System, lactate dehydrogenase, cytogenetic risk, transplant eligibility, and complete remission status. Transplant-eligible patients with active MM with MGUS-like phenotype showed PFS and OS rates at 5 years of 79% and 96%, respectively. In this subgroup, there were no differences in PFS and OS according to complete remission and measurable residual disease status. Application of the algorithm in two independent series of patients with AL predicted for different survival. CONCLUSION We developed an open-access algorithm for the identification of MGUS-like patients with distinct clinical outcomes. This phenotypic classification could become part of the diagnostic workup of MM and AL amyloidosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Monoclonal Gammopathy of Undetermined SignificanceImmunoglobulin Light-chain AmyloidosisParaproteinemiasMultiple MyelomaHumansClinical RelevanceDisease ProgressionPhenotype

Autor:innen und Institutionen

  • Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Universidad de Navarra, CCUN, IDISNA, CIBERONC, Pamplona, Spain.
  • Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain.
  • Hematology Department, Hospital Universitario 12 de Octubre, CIBERONC, Instituto de Investigación IMAS12, Madrid, Spain.
  • Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic.
  • Myeloma Center/Division of Hematology Oncology/Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR.
  • Department of Molecular Medicine, University of Pavia and Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

ORCID-Profile: Luis-Esteban Tamariz-Amador, Noemi Puig, Maria-Teresa Cedena, Camila Guerrero, Tomas Jelínek, Paolo Milani, Lourdes Cordon, Marta Lasa, Rosalinda Termini, Albert Oriol, Miguel-Teodoro Hernandez, Luis Palomera, Javier de la Rubia, Rafael Rios, Maria-Esther Gonzalez, Mercedes Gironella, Valentin Cabañas, Isabel Krsnik, Albert Perez-Montaña, Verónica González-Calle, Paula Rodriguez-Otero, Roman Hajek, Fritz Van Rhee, Giovanni Palladini, Giampaolo Merlini, Alberto Orfao, Joaquin Martinez-Lopez, Juan-Jose Lahuerta, Laura Rosiñol, Maria-Victoria Mateos, Jesus F San-Miguel, Bruno Paiva

Zitieren

APA

Burgos, L., Tamariz-Amador, L. E., Puig, N., Cedena, M. T., Guerrero, C., Jelínek, T., Johnson, S., Milani, P., Cordon, L., Perez, J. J., Lasa, M., Termini, R., Oriol, A., Hernandez, M. T., Palomera, L., Martinez-Martinez, R., de la Rubia, J., de Arriba, F., Rios, R., …, & PETHEMA/GEM Cooperative Group (2023). Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance–Like Phenotype in Patients With Monoclonal Gammopathies. Journal of Clinical Oncology. https://doi.org/10.1200/jco.22.01916

Vancouver

Burgos L, Tamariz-Amador LE, Puig N, Cedena MT, Guerrero C, Jelínek T, et al. Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance–Like Phenotype in Patients With Monoclonal Gammopathies. Journal of Clinical Oncology. 2023. doi:10.1200/jco.22.01916

BibTeX
@article{Burgos2023,
  author = {Burgos, Leire and Tamariz-Amador, Luis-Esteban and Puig, Noemi and Cedena, Maria-Teresa and Guerrero, Camila and Jelínek, Tomas and Johnson, Sarah and Milani, Paolo and Cordon, Lourdes and Perez, Jose J and Lasa, Marta and Termini, Rosalinda and Oriol, Albert and Hernandez, Miguel-Teodoro and Palomera, Luis and Martinez-Martinez, Rafael and de la Rubia, Javier and de Arriba, Felipe and Rios, Rafael and Gonzalez, Maria-Esther and Gironella, Mercedes and Cabañas, Valentin and Casanova, Maria and Krsnik, Isabel and Perez-Montaña, Albert and González-Calle, Verónica and Rodriguez-Otero, Paula and Maisnar, Vladimir and Hajek, Roman and Van Rhee, Fritz and Jimenez-Zepeda, Victor and Palladini, Giovanni and Merlini, Giampaolo and Orfao, Alberto and de la Cruz, Javier and Martinez-Lopez, Joaquin and Lahuerta, Juan-Jose and Rosiñol, Laura and Blade, Joan and Mateos, Maria-Victoria and San-Miguel, Jesus F and Paiva, Bruno and PETHEMA/GEM Cooperative Group, PETHEMA/GEM Cooperative Group},
  title = {Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance–Like Phenotype in Patients With Monoclonal Gammopathies},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  doi = {10.1200/jco.22.01916}
}
Kostenlos starten →